ABL Bio is hosting an online and offline corporate briefing to strengthen communication with investors. The event will showcase global partnering outcomes from the recent BIO International Convention (BIO USA 2026), key pipeline development updates, and the company's next-generation antibody-drug conjugate (ADC) strategy.

ABL Bio announced that it will hold a corporate briefing on the 7th, targeting individual investors, analysts, and institutional investors. The offline event for institutional investors and securities analysts will be held privately. The online briefing for individual investors will be broadcast live on the company's official YouTube channel starting at 3:30 PM.

At this briefing, the company will introduce its commercialization strategy for 'Grabody-B,' a blood-brain barrier (BBB) shuttle platform, as well as the development status of immuno-oncology therapeutics utilizing 'Grabody-T,' a 4-1BB-based bispecific antibody platform. In particular, the key presentation will cover the development progress of givastomig (ABL111) and lagistomig (ABL503), along with development strategies for next-generation cancer treatments, including bispecific ADCs and dual-payload ADCs.

ABL Bio is developing treatments for cancer and degenerative brain diseases based on its proprietary bispecific antibody platform technology. The company is expanding collaborations with global pharmaceutical companies to strengthen its new drug development competitiveness. Currently, a total of 10 clinical projects, including ABL301, ABL001, ABL111, ABL503, ABL105, ABL104, ABL103, ABL202, ABL206, and ABL209, are underway in the United States, South Korea, China, and Australia.

Regarding key achievements, ABL301 completed Phase 1 clinical trials in the United States, and subsequent development will be taken over by global pharmaceutical company Sanofi. Both biliary tract cancer treatment ABL001 and immuno-oncology drug ABL111 have received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA).

ABL Bio CEO Lee Sang-hoon stated, "Through this briefing, we plan to share the company's vision and R&D progress with a diverse group of investors." He added, "We will provide detailed explanations of our achievements at BIO USA, our core platform technologies, and our next-generation ADC development strategy to deepen understanding of the company's growth direction."

Alongside expanding its clinical-stage pipeline, ABL Bio is accelerating its push into the global bio market by continuously conducting R&D on new platforms, including next-generation bispecific ADCs and dual-payload ADCs.

[This article was written with the assistance of AI. This article is not intended to solicit investment, and the final decision and responsibility for investments lie solely with the investor.]